Research
Less-frequent GLP-1 dosing: the evidence gap
The approved GLP-1 weight products are dosed once weekly, and that weekly schedule is what every pivotal trial studied. There is no randomized evidenc
The approved GLP-1 weight products are dosed once weekly, and that weekly schedule is what every pivotal trial studied. There is no randomized evidence for less-frequent (e.g., every-other-week) dosing for weight management; it is an untested schedule, not an evidence-backed one.
What the trials establish
Weekly dosing isn't arbitrary — it reflects the drugs' roughly week-long half-lives and the schedule used throughout the STEP and SURMOUNT programs. Stretching the interval changes the pharmacokinetics in ways no weight-management RCT has evaluated.
Marketing sometimes frames less-frequent dosing as a cost-saving 'microdose-adjacent' strategy. That may reduce cost, but it also moves further from the studied regimen, and there is no trial showing the weight outcomes survive the change.
This is a clean example of the cluster's theme: a plausible-sounding modification with zero randomized support. The honest label is 'unstudied,' and this page marks it as such rather than filling the gap with inference.
| Trial | Population | N | Result | Citation | Identifiers |
|---|---|---|---|---|---|
| STEP 1 | Adults with overweight/obesity, without diabetes | 1,961 | Mean weight change about -14.9% vs -2.4% placebo | Wilding JPH, et al. N Engl J Med 2021;384:989-1002 | NCT03548935 · PMID 33567185 · DOI |
| SURMOUNT-1 | Adults with obesity, without diabetes | 2,539 | Up to about -20.9% at 15 mg vs -3.1% placebo | Jastreboff AM, et al. N Engl J Med 2022;387(3):205-216 | NCT04184622 · PMID 35658024 · DOI |
Identifiers verified against ClinicalTrials.gov and PubMed. Machine-readable dataset: studies.json · studies.csv.
What remains unknown
Across this topic, the recurring gap is the same: the randomized evidence describes approved products at studied doses, while compounded and deliberately sub-therapeutic 'microdose' use sits outside it. This page marks that boundary rather than blurring it.
What the evidence shows
- The cited trials carry verified NCT, PMID, and DOI identifiers and studied approved products at labeled doses.
- Findings here reflect those trials' actual results and populations.
What the evidence does not show
- That a compounded or microdose version reproduces these results — it has not been studied.
- That approved-product evidence transfers automatically to compounded formulations.
Frequently asked questions
Can I take a GLP-1 less often?
No trial supports less-frequent dosing for weight loss; the studied schedule is weekly. Discuss any change with a prescriber.
Does spacing doses save money safely?
It may cut cost but has no efficacy evidence and alters the studied regimen.
Related: evidence database · research hub. Compounded medications are not FDA approved.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.